Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.

Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M, Chen X, Calvisi DF.

Cell Cycle. 2013 Jul 1;12(13):1999-2010. doi: 10.4161/cc.25099. Epub 2013 Jun 6.

PMID:
23759595
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.

J Surg Res. 2012 Aug;176(2):542-8. doi: 10.1016/j.jss.2011.10.045. Epub 2011 Nov 21.

PMID:
22261591
[PubMed - indexed for MEDLINE]
3.

AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.

Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, Armbruster J, Fan L, Lee SA, Jiang L, Dombrowski F, Evert M, Chen X, Calvisi DF.

Hepatology. 2012 Mar;55(3):833-45. doi: 10.1002/hep.24736. Epub 2011 Dec 19.

PMID:
21993994
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.

Evert M, Calvisi DF, Evert K, De Murtas V, Gasparetti G, Mattu S, Destefanis G, Ladu S, Zimmermann A, Delogu S, Thiel S, Thiele A, Ribback S, Dombrowski F.

Hepatology. 2012 May;55(5):1473-84. doi: 10.1002/hep.25600. Epub 2012 Apr 4.

PMID:
22271091
[PubMed - indexed for MEDLINE]
5.

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.

Anticancer Res. 2010 Dec;30(12):4951-8.

PMID:
21187475
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Akt and mTORC1 have different roles during liver tumorigenesis in mice.

Kenerson HL, Yeh MM, Kazami M, Jiang X, Riehle KJ, McIntyre RL, Park JO, Kwon S, Campbell JS, Yeung RS.

Gastroenterology. 2013 May;144(5):1055-65. doi: 10.1053/j.gastro.2013.01.053. Epub 2013 Jan 30.

PMID:
23376645
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.

Du W, Gerald D, Perruzzi CA, Rodriguez-Waitkus P, Enayati L, Krishnan B, Edmonds J, Hochman ML, Lev DC, Phung TL.

Lab Invest. 2013 Oct;93(10):1115-27. doi: 10.1038/labinvest.2013.98. Epub 2013 Aug 12.

PMID:
23938603
[PubMed - indexed for MEDLINE]
8.

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.

Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.

Anticancer Res. 2012 Jul;32(7):2531-6.

PMID:
22753710
[PubMed - indexed for MEDLINE]
9.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.

Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.

PMID:
23167739
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.

Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.

Mol Cancer. 2010 Sep 22;9:256. doi: 10.1186/1476-4598-9-256.

PMID:
20860815
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.

Li Y, Wang X, Yue P, Tao H, Ramalingam SS, Owonikoko TK, Deng X, Wang Y, Fu H, Khuri FR, Sun SY.

J Biol Chem. 2013 May 10;288(19):13215-24. doi: 10.1074/jbc.M113.463679. Epub 2013 Mar 27.

PMID:
23536185
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.

Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ.

Gynecol Oncol. 2014 Feb;132(2):468-73. doi: 10.1016/j.ygyno.2013.11.027. Epub 2013 Dec 4.

PMID:
24316308
[PubMed - indexed for MEDLINE]
13.

E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.

Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS.

Gastroenterology. 2008 Oct;135(4):1322-32. doi: 10.1053/j.gastro.2008.07.012. Epub 2008 Jul 17.

PMID:
18722373
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.

Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, Calvisi DF, Chen X.

J Hepatol. 2012 Sep;57(3):577-83. doi: 10.1016/j.jhep.2012.04.026. Epub 2012 May 19.

PMID:
22617155
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM.

J Hepatol. 2009 Oct;51(4):725-33. doi: 10.1016/j.jhep.2009.03.028. Epub 2009 Jun 12.

PMID:
19665249
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

PMID:
22559167
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.

Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.

Anticancer Drugs. 2013 Oct;24(9):889-98. doi: 10.1097/CAD.0b013e328363c64e.

PMID:
23838676
[PubMed - indexed for MEDLINE]
18.

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.

Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ.

Cancer Res. 2003 Jan 15;63(2):364-74.

PMID:
12543789
[PubMed - indexed for MEDLINE]
Free Article
19.

SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.

Gen Y, Yasui K, Nishikawa T, Yoshikawa T.

Cancer Sci. 2013 Jul;104(7):810-6. doi: 10.1111/cas.12155. Epub 2013 Apr 16.

PMID:
23510069
[PubMed - indexed for MEDLINE]
20.

Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.

Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E.

PLoS One. 2013;8(2):e57289. doi: 10.1371/journal.pone.0057289. Epub 2013 Feb 21.

PMID:
23437362
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk